<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: Pfizer Is &#8216;Cozying Up&#8217; To Korean Regulators?</title>
	<atom:link href="http://www.pharmalot.com/2008/11/pfizer-accused-of-cozying-up-to-korean-regulators/feed" rel="self" type="application/rss+xml" />
	<link>http://www.pharmalot.com/2008/11/pfizer-accused-of-cozying-up-to-korean-regulators/</link>
	<description>News, Comment and Conversation</description>
	<pubDate>Fri, 10 Feb 2012 21:36:22 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.2</generator>
		<item>
		<title>By: Observer</title>
		<link>http://www.pharmalot.com/2008/11/pfizer-accused-of-cozying-up-to-korean-regulators/#comment-383033</link>
		<dc:creator>Observer</dc:creator>
		<pubDate>Wed, 26 Nov 2008 13:31:47 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/?p=18050#comment-383033</guid>
		<description>While it is difficult to defend a company as corrupt as Pfizer, particularly under Ian Read's commercial direction, it is comical to hear the cries that “it’s not fair for HIRA to apply different standards to local and foreign firms" in South Korea.  Historically, different standards have been the norm with advantages going to local companies who have paid the "price."  It is therefore not difficult to conclude that Pfizer is either overtly paying (e.g., so-called "clinical studies") or covertly (no explanation necessary) contrubuting to what has historically been a corrupt industry and ministry in the Republic of Korea.</description>
		<content:encoded><![CDATA[<p>While it is difficult to defend a company as corrupt as Pfizer, particularly under Ian Read&#8217;s commercial direction, it is comical to hear the cries that “it’s not fair for HIRA to apply different standards to local and foreign firms&#8221; in South Korea.  Historically, different standards have been the norm with advantages going to local companies who have paid the &#8220;price.&#8221;  It is therefore not difficult to conclude that Pfizer is either overtly paying (e.g., so-called &#8220;clinical studies&#8221;) or covertly (no explanation necessary) contrubuting to what has historically been a corrupt industry and ministry in the Republic of Korea.</p>
]]></content:encoded>
	</item>
</channel>
</rss>

<!-- Dynamic Page Served (once) in 0.149 seconds -->

